Calliditas Therapeutics to Present Nefecon Data at the 17[th] International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data presentations from the NeflgArd Phase 3 Study at the 17[th] International Symposium on IgA Nephropathy (IIgANN).Investigators will be presenting additional analyses of the Phase 3 NefIgArd study's 2-year data with Nefecon (TARPEYO[®] (budesonide) delayed-release capsules/Kinpeygo[®]) for the treatment of Primary IgA nephropathy (IgAN), along with the biomarker data from the NeflgArd study. IIgANN will be held virtually and in person in Tokyo, Japan, September 25-27, 2023.